Mergers and Acquisitions

Sanofi buys Principia Biopharma for $3.68 billion or $100 per share. The acquisition of Principia Biopharma, which develops treatment methods for severe immune diseases, will strengthen Sanofi's research capacity in areas such as autoimmune and allergic diseases. The deal is scheduled to be closed in Q4 2020.